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Summary

Since March 2013, animal use for cosmetics testing for the European market has been banned. This requires a renewed view on
risk assessment in this field. However, in other fields as well, traditional animal experimentation does not always satisfy requirements in safety testing, as the need for human-relevant information is ever increasing. A general strategy for animal-free test
approaches was outlined by the US National Research Council’s vision document for Toxicity Testing in the 21st Century in 2007.
It is now possible to provide a more defined roadmap on how to implement this vision for the four principal areas of systemic
toxicity evaluation: repeat dose organ toxicity,
carcinogenicity, reproductive toxicity and allergy
induction (skin sensitization), as well as for the
evaluation of toxicant metabolism (toxicokinetics)
(Fig. 1). CAAT-Europe assembled experts from
Europe, America and Asia to design a scientific
roadmap for future risk assessment approaches
and the outcome was then further discussed and
refined in two consensus meetings with over 200
stakeholders. The key recommendations include:
focusing on improving existing methods rather
than favoring de novo design; combining hazard
testing with toxicokinetics predictions; developing integrated test strategies; incorporating new
high content endpoints to classical assays; evolv- Fig. 1: The five areas of systemic toxicity testing
http://dx.doi.org/10.14573/altex.1406091

* a report of t 4 – the transatlantic think tank for toxicology, a collaboration of the toxicologically oriented chairs in Baltimore, Konstanz and
Utrecht, sponsored by the Doerenkamp-Zbinden Foundation.

All authors contributed to this report as individuals, and not as representatives of their organizations. Statements and opinions expressed
in this review do not reflect official policies or any other form of positioning of the affiliations of the authors. The text is a consensus
document expressing not at each point the exact position of each author. Statements only reflect the majority of the group and not all
minority opinions have been included.
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ing test validation procedures; promoting collaboration and data-sharing of different industrial sectors; integrating new disciplines, such as systems biology and high throughput screening; and involving regulators early on in the test development process.
A focus on data quality, combined with increased attention to the scientific background of a test method, will be important drivers.
Information from each test system should be mapped along adverse outcome pathways. Finally, quantitative information on all
factors and key events will be fed into systems biology models that allow a probabilistic risk assessment with flexible adaptation
to exposure scenarios and individual risk factors.
Keywords: safety testing, animal-free testing, systemic toxicity, adverse outcome pathways

1 Introduction and background

The discussion leading to this summary report started with the
7th Amendment to the Cosmetics Directive 76/768/EEC1, which
called for a complete ban of testing on vertebrate animals for the
toxicological characterization of cosmetics ingredients in 2013.
The European Commission asked experts to evaluate the availability of alternative non-animal methods. Their conclusion that
alternative methods would not be available during the next 10
years (Adler et al., 2011) met with some criticism (Taylor et al.,
2011), but was mostly endorsed by an independent expert group
invited by CAAT also including specialists from Japan and the
USA (Hartung et al., 2011). They also noted that significant ad-

vances had been made in the time between the publication of the
Adler Report and the evaluation by the international group of experts. The next step, i.e., assembling experts to create a perspective for the future, was initiated by CAAT-Europe in a series of
commissioned white papers on sensitization, repeated dose organ
toxicity, toxicokinetics, carcinogenicity and reproductive toxicity. Importantly, this work addressed a broad range of chemical
testing, including also the fields of drugs, pesticides and industrial chemicals in addition to cosmetics ingredients. A workshop
with 35 experts discussed these white papers. This activity resulted in the extensive report A roadmap for the development of
alternative (non-animal) methods for systemic toxicity testing
(Basketter et al., 2012). To involve all potential stakeholders, this

Fig. 2 Timeline of events leading to this public expert consultation report
The 7th amendment of the European Cosmetics Directive required the phasing out of animal testing to be completed by 2013. The
European Commission evaluated the availability of non-animal methods and the outcome was published (Adler et al., 2011). The
conclusions of that report were confirmed by independent experts (Hartung et al., 2011). In order to outline a roadmap for further
development of non-animal methods for addressing systemic toxicity, an expert consortium was convened in a series of CAAT-Europe
workshops to elaborate on the issue. As a result, an extensive report on the roadmap for non-animal methods for systemic toxicity testing
was published (Basketter et al., 2012) and presented for a public expert consultation in 2012 in Brussels and in 2013 in Washington at an
FDA-hosted event. The present report summarizes the recommendations resulting from the public expert consultation in which over
200 experts from academia, industry and regulatory authorities were involved. Grey boxes refer to actions taken by CAAT/CAAT-Europe.
1 http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/antest/(2)_executive_summary_en.pdf
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roadmap was presented in March 2012 in Brussels2 by several
experts in front of about 200 stakeholders from governmental
organizations, academia, industry and NGOs from all over the
world (Fig. 2). A second workshop, Scientific roadmap for the
future of animal-free systemic toxicity testing, similar in size and
scope, was organized in Washington at the FDA in May 2013 to
give updates on the Basketter report and scientific advances in
the fields3.
Each of the lectures on the five major fields still requiring
better non-animal safety testing methods (Fig. 1) was followed
by one hour of intensive discussion to consolidate or improve
the suggested strategies. Here we report the final outcome. This
roadmap is expected to pave the way for a new toxicology that
can better predict the effect of chemicals on humans, using fewer or even no vertebrate animals.
2 Animal models

A successful strategy to replace animal testing must take its
starting point from the analysis of the current technology. The
weaknesses of animal testing could then be avoided by the new
approach (Fig. 3). It must be noted that rational comparisons are
made difficult by the fact that almost all of the currently used
animal models have never been formally validated. The rationale of their use is therefore not based on scientific data (Hartung
and Leist, 2008).
Some of the problems related to animal models derive from
the high doses that are tested and the multiplicity of endpoints
that are measured. Experts claim, that “Half of all chemicals,
whether natural or synthetic, are positive in high-dose rodent

cancer tests. These results are unlikely to be relevant at the low
doses of human exposure.” (Ames and Gold, 2000). Many of the
attendees expressed the opinion that widespread knowledge on
the limited value of certain animal studies frequently contributes to the decision by authorities to waive testing.
The lack of predictivity of animal models is particularly apparent from the field of drug development (Leist and Hartung,
2013). Only 8% of drugs entering clinical phase I (first human
dose) gain approval by authorities and half of them fail in phase
III4. US Health and Human Services Secretary Mike Leavitt
commented that “currently, nine out of ten experimental drugs
fail in clinical studies because we cannot accurately predict
how they will behave in people based on laboratory and animal
studies.” 5
The conclusions are easily drawn: We need human-predictive, rapid and economical methods to evaluate whether or not a
compound, no matter if chemical, drug or cosmetic ingredient,
is safe for intended human use.
3 Future safety science and pathways of toxicity

A key step in the paradigm shift in toxicology, as far as regulatory authorities are concerned, was the 2007 US National Research Council report Toxicity Testing in the 21st Century – a
Vision and a Strategy (NRC, 2007; Leist et al., 2008a). It promoted the idea that the number of ways that a chemical or drug
could disturb a cell is finite and can therefore be identified by
appropriate screening methods. Quantitative information on
the concentration-dependence of such disturbances can be used
to predict the overall network of cellular regulatory reactions
Fig. 3: Problems with animal experiments
To assess the hazard posed by substances
humans are exposed to, all available
approaches need to be evaluated for
their usefulness. The present system of
animal testing needs critical evaluation
of its predictive power for human safety.
The limitations of animal testing, which is
often considered the “gold” standard, may
compromise human safety and pose an
economic threat. Under such conditions, its
ethical acceptability is also doubtful.

2 The forum was co-organized by Center for Alternatives to Animal testing (CAAT), Cosmetics Europe, Doerenkamp-Zbinden Foundation, European

Chemical Industry Council (CEFIC), European Consensus Platform for Alternatives (ECOPA), European Society for Alternatives to Animal Testing
(EUSAAT), European Society for Toxicology in vitro (ESTIV), US EPA ToxCastTM, Humane Society International (HSI), Institute for In-vitro Sciences
(IIVS) and In-vitro Testing Industrial Platform (IVTIP).
3 The forum was co-organized by Agilent Technologies, American Cleaning Institute (ACI), Animal Research & Development Foundation (ARDF),

American Society for Cellular and Computational Toxicology (ASCCT), Center for Alternatives to Animal testing (CAAT), CropLife Canada, CropLife
America, FDA Center for Food Safety and Advanced Nutrition (CFSAN), Grocery Manufacturer Association (GMA), Human Toxicology Project
Consortium, Humane Society of the United States (HSUS), Institute for Invitro Sciences (IIVS), National Institute for Environmental Health Sciences
(NIEHS), People for the ethical Treatment of Animals (PeTA) and The Hamner Institute.
4 http://www.the-scientist.com/?articles.view/articleNo/15910/title/More-Compounds-Failing-Phase-I/
5 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108576.htm
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Fig. 4: Illustration of the concept of Pathways of Toxicity (PoT)
PoT are cellular pathways of metabolism and regulation. Interference with them can lead either to adaptive or adverse (maladaptive)
responses. Prediction of the outcome requires computational modeling. A toxicant challenge may trigger different responses at different
concentrations, leading to various reactions in the cell. A low target site concentration (corresponding to a “no observed effect level”
(NOEL) and being much lower than the “no observed adverse effect level” (NOAEL)) may not affect the normal biological function. A
medium concentration (in the range of the NOAEL) may induce an adaptive stress. Whether this results in a return to normal function or to
an altered biological state depends on genetic and environmental factors and their interaction (G x E). An even higher concentration (much
larger than NOAEL or NOEL) might either lead to an adaptive stress response or a complete loss of function. Here, G x E factors also play
a key role in the decision whether a compound leads to cell injury, morbidity and mortality.

(Hartung et al., 2012; Blaauboer et al., 2012). Deviations from
normal at important control points could be related to adverse
effects of chemicals and have been termed pathways of toxicity (PoT) (Kleensang et al., 2014). Individual susceptibilities to
toxicant actions are determined by genetic heterogeneity of the
human population (G), but also by additional environmental factors (E) (Fig. 4). The combination of high throughput screening
assays with traditional cellular assays has been supplemented
by in vitro-in vivo mathematical extrapolations, systems biology
(computer models of cell regulation) and other approaches by
many leading academic and governmental organizations to provide integrated testing strategies (Leist et al., 2012a,b; Sturla et
al., 2014; Hartung et al., 2013b; Kavlock et al., 2012; Andersen
et al., 2011; Hartung and McBride, 2011; Bouhifd et al., 2014;
Rossini and Hartung, 2012).
New approaches to safety testing require new strategies to
stringent but flexible evaluation of the suitability and performance of methods. Methods suggested by the Evidence-based
Toxicology Collaboration (European and US branches, http://
www.ebtox.com) will be helpful in this process (Stephens et
al., 2013). The risk classification itself is also likely to undergo
fundamental changes. At present, using a very limited number
of animal tests, a chemical is classified as toxic or non-toxic
(deterministic risk assessment) at a given exposure level. The
much richer information provided by the new approaches and
the progress of safety sciences could form a basis for probabilistic risk assessment (Paparella et al., 2013). This would al344

low for more rational and science-based regulatory decisions by
assembling information from a tailored set of tests adapted to
different types of questions and scenarios of exposure and risk
assessment (Fig. 5).
4 General forward strategies

While discussing the five specific toxicological domains, the experts identified issues relevant to all areas of in vitro methods.
Joint knowledge management and sharing of expertise between
different sectors, stakeholders and application domains were
identified as important drivers for accelerated progress, in addition to accelerated test establishment and validation, and better
use of computational toxicology methods (Fig. 6).
Sharing of data would hopefully lead to the creation of a human safety database, bigger and more complete than existing
ones (e.g. OPENTOX, EPA, TOXBANC, IMI activities). Most
importantly, it would be more accessible and should be tailored
for in vitro-in vivo comparisons as well as data mining by nonspecialists in bioinformatics. The focus would not be on data
collection as such, but on the accessory information linked to
the primary outcome data as far as mechanisms of toxicity are
concerned. As there are major hurdles (e.g., intellectual property
rights and industrial competitiveness issues) to be overcome, it
is clear that substantial incentives must be granted to encourage
industry to share their proprietary data (Fig. 7).
Altex 31, 3/14
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Fig. 5: Vision of a smooth transition from current
to future toxicology in safety science
It is envisaged that the types of test systems employed will
change over the time course of the establishment of a new
safety science. At present, complex test systems that are
specific for organ functions and developmental stages are
preferentially used. Only few programs use simple assays of
elementary biochemical and cellular function (e.g., ToxcCastTM
Program). Over time, more and more critical biomarkers of
toxicity may be identified by the application of HCS (highcontent screening) and omics technologies to the complex
systems, and simple test systems may suffice to measure key
processes (Rossini and Hartung, 2012). Case studies, e.g.,
from PBPK (physiologically based pharmacokinetic modeling)
and skin sensitization fields, could be used as learning models
for the transition. The principles of evidence-based toxicology
and the resulting quality control will lead to an accelerated
method development and validation. Over time, the goal is
to shift from the present deterministic risk classification to a
probabilistic risk assessment.

Fig. 6: General points to consider when moving forward
towards new approaches for systemic toxicity testing
While discussing solutions for the five toxicological endpoints
(carcinogenicity, reproductive toxicity, repeated dose organ
toxicity, sensitization and toxicokinetics), the experts agreed
that several suggestions apply equally to all five areas under
investigation. These general suggestions are summarized here.

None of the future challenges in the field of in vitro toxicology can be addressed by individual test systems. The solution
will rather lie in the construction of batteries of tests to be combined in integrated testing strategies (ITS). This will need to
be considered right from the conception of a test, throughout
its development and especially during the evaluation of its performance. The latter evaluation needs to consider the test alone,
but also in the context of the added value it brings to a test
battery. More research and experimentation is required on how
to build ITS. One example of a flexible, yet fully quantitative
approach, is the Bayesian network (McDowell and Jaworska,
Altex 31, 3/14

Fig. 7: Creation of a high quality database for relating in vivo
and in vitro information
The key players (pharmaceutical, chemical and cosmetics industry,
basic research and regulators) share common goals that are of high
value to them. The benefit of working together should outweigh
disadvantages (opening of proprietary databases). This would allow
the generation of a large, high quality database of in vitro toxicity
data. It should be publicly available, include rich data that informs
on the mode of action of compounds and allows for in vitro – in vivo
correlations. It should also be quality controlled and suitable for case
studies. This can be achieved by joint projects and the common use
of legacy data from hitherto proprietary in-house databases. The
collection of human data by micro-dosing, from clinical trials and
from epidemiological studies plays a major role.
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Fig. 8: Example for the use of Bayesian networks in the
establishment of integrated testing strategies
LLNA (local lymph node assay) potency prediction is used here as
an example from the area of skin sensitization. Information from
different assays (circles) is fed into the network. The dimension of
the circles represents mutual information values; the length of the
arrows has no mathematical correlation. For instance, information
can be obtained on how the in vivo outcome (LLNA: local lymph
node assay) is predicted by physicochemical compound properties
(such as molecular weight or lipophilicity (Kow)), biological assays
(e.g., GARD assay or dendritic cell assay) and peptide reactivity
measures (DPRA: direct peptide reactivity assay). The advantage
of the approach is that it can be coupled to other networks or other
assays, as they are desired and become available. The original
paper (Jaworska and Hoffmann, 2010) contains all the details on
the background.

Fig. 9: Strategies to improve in vitro test systems
Test systems that already have been developed can still improve
in quality and robustness to arrive relatively quickly at
predictive test systems fit for regulatory use. A list of features to
be considered has been compiled here.

2002; Jaworska and Hoffmann, 2010; Jaworska et al., 2010,
2011), which has been applied successfully in the area of skin
sensitization (Fig. 8). Input of the field of machine-learning is
envisaged to be very important for optimal strategic designs of
ITS (Hartung et al., 2013b).
5 Strategies to improve test systems

Alternative in vitro methods have been developed for all toxicological questions, including even the most complex fields,
ranging from developmental neurotoxicity (DNT) to xenobiotic
metabolism (Adler et al., 2011; Basketter et al., 2012; Leist et
al., 2012a, 2008b; van Thriel et al., 2012; Smirnova et al., 2014;
Taylor et al., 2011). Many of these methods should be formally
validated for immediate use, or they could form the basis for
accelerated further development. Optimization of existing systems is an important part of the strategy to accelerate the implementation of a mostly animal-free safety science, in addition to
the more time demanding development of entirely new methods
(Fig. 9). One specific way to improve available tests is the incorporation of highly information-rich endpoints provided by
346

Fig. 10: Overview of different omics technologies that
can inform on chemicals’ adverse outcome pathways and
underlying modes of action
Omics technologies provide data-rich endpoints. The biological
information flow in a cell leads from gene sequences (the code)
via RNA (the messages) to enzymes and other functional proteins
(the tools). Within this infrastructure small molecule metabolites
may be regarded as the goods that are produced and traded.
They comprise energy substrates, building blocks and signaling
messengers. As there are feedback loops between all levels,
the different omics technologies address these four organization
levels. The disturbance of a cell by chemicals may be measured
by any single technique. Combinations of more than one approach
lead to a better prediction of the true human situation.
Altex 31, 3/14
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omics technologies. Where classical methods measure only one,
or few, endpoints (e.g., metabolites or gene expression levels),
the new approaches can yield thousands of data points simultaneously, and provide information on a genome-wide scale (Fig.
10) and, thus, allow insights into the reaction of a network.
6 Specific approaches for the five toxicological
endpoints still lacking validated replacement
methods

A detailed strategy has been elaborated for each endpoint and
described in detail (Basketter et al., 2012). The consensus meeting of the roadmap initiative highlighted specific points for immediate attention and action:
6.1 Skin Sensitization

Although the sensitization process is a disease-free state, subsequent exposures can lead to allergic contact dermatitis, the
most common adverse effect of chemicals on human health.
One in 5 adults suffers contact allergy to one chemical or another (Peiser et al., 2012). This area differs from others as a
large amount of human data is available. Moreover, the gen-

eral mechanisms of sensitization are well-defined. There are
three well-developed animal models (Buehler Guinea Pig
Test, Guinea Pig Maximization Test (GPMT) and Mouse Local Lymph Node Assay (LLNA)) currently used to identify
chemicals with toxic potential. The LLNA, which is already
a step towards refinement and reduction of the use of animals,
is the preferred method for safety assessment as it provides
a quantitative value (the concentration of the chemical which
causes a threshold positive response (EC3)) that can determine
the potency of the sensitizer.
Already over a dozen different in vitro tests to identify sensitizers have been submitted to the European Union Reference
Laboratory for Alternatives to Animal Testing (EURL ECVAM).
Currently, two of these are validated for risk assessment. These
are the direct peptide reactivity assay (DPRA), based on the
chemical understanding and correlation with sensitization, and
the human cell line activation test (h-CLAT), based on the activation of dendritic-like cells (Bauch et al., 2011; Sakaguchi
et al., 2006; Ashikaga et al., 2010). The KeratinoSense™ luciferase-reporter gene model (based on the anti-oxidant response
element in the HaCaT keratinocyte cell line) (Natsch, 2010; Andreas et al., 2011) has already been validated by Givaudan and
is accepted by OECD. Integrated testing strategies (ITS) will be

Fig. 11: Example for the concept of adverse outcome pathways (AOPs) from the area of skin allergy
The general scheme of an AOP is illustrated in the upper panel. The AOP provides a mechanistic link between a chemical structure and
the response of the organism to the chemical. At increasing levels of complexity, the xenobiotic’s action is assumed to be started by a
molecular initiating event, followed by cellular and organ responses that eventually explain the effect on the organism. The middle panel
gives an example by depicting the events leading to skin sensitization. Understanding the underlying pathophysiology is necessary to
create a set of in vitro models for all key events. The lower panel shows an example of a specific AOP for skin sensitization. Key
event 1 corresponds to the molecular initiating event. Further key events are shown and each of them may be modeled in vitro.
Combination of such in vitro tests in an integrated strategy (ITS) would allow comprehensive predictions for unknown xenobiotics.
Altex 31, 3/14
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the way forward, as each assay on its own has 80% accuracy, but
if combined in an ITS, 90% accuracy can be reached (Bauch et
al., 2012). This level of predictivity would perform better than
the validated LLNA. Thus, an ITS would fully replace the existing animal models.
Skin sensitization is a field in which several formally validated methods and ITS are expected to emerge in the near
future. The reasons for this are the following: first, for skin
sensitization the validation process has clear anchors: this
is the only toxicological domain that is based on a formally
validated animal test model (LLNA). Moreover, a large set of
human data on positive control compounds is available, e.g.,
from diagnostic patch testing in dermatology clinics. Second,
the mechanisms of skin sensitization are well understood, and
the individual steps are amenable to modeling. Third, several
in vitro models that seek to mimic each single step in the pathway are already available, and they now need only to be combined in an ITS. CAAT organized a workshop on ITS using the
example of skin sensitization in June 2013 in Ranco, Italy; the
respective report is currently being completed.
The application of the OECD-promoted concept of “adverse
outcome pathways” (AOPs) to skin sensitization is relatively
straightforward. Virtually all key events of the AOP already
are covered by in vitro assays (Fig. 11)6. Despite this favorable situation, validation of a complete ITS for skin sensitization will require further work. It is, for instance, not yet clear
how the individual tests that cover the steps of the AOP will
be combined, including how much weight is given to the results of each assay and how the decision points of tiered testing
would be structured. The final prediction model must be built
as a whole on the assembly of tests and on the ITS rules linking them. The process of building and optimizing this overall
test strategy is made difficult by the fact that the LLNA, even
though it is one of the most advanced in vivo methods, can yield
false-negative and false-positive results. Despite these weaknesses, and although human data are available as an alternative reference point, the LLNA is the only accepted reference
for the determination of potency and for providing background
data for ITS validation.
The conclusions on the status and roadmap for skin sensitization testing are as follows:
– Many non-animal methods for skin sensitization testing have
been proposed and some of them have been/will be validated
for the purpose of hazard identification. The development of
non-animal methods for the evaluation of the relative skin sensitizing potency of contact allergens will require more work.
– Better measurements and tests for exposure are needed, and
little is known about how to assess mixtures yet.
– Complications may arise when there is a need to test hydrophobic compounds or formulations as the proposed models
may not be adequate. These problems must be tackled sooner
rather than later and the applicability of each model should
be assessed accordingly. This will provide opportunities for
the development of other assays with other applicability domains.

– Many other areas of toxicology can follow skin sensitization
as a good example where a detailed understanding of mechanisms can lead to the development of specific assays needed
to identify compound toxicity.
– Computational models based on quantitative structure-activity relationships (QSARs) provide promising tools to identify
sensitizers, as the toxicity of the chemical is implicit in its
structure. There have been major advances in QSAR models,
although studies use data from the LLNA rather than human
data and have difficulties in obtaining accuracy in models for
“moderate” sensitizers (Li et al., 2007).
6.2 Repeated dose toxicity

Repeated dose testing (RDT) consists in the evaluation of a
chemical’s potential to cause chronic toxicity and organ-specific
toxicities. Classically, tests for RDT are based on 4 (sub-acute
toxicity), 13 (sub-chronic toxicity) and 26-102 (chronic toxicity) week rodent and non-rodent studies. Toxicity occurs after a
chemical is absorbed into the general circulation. There is great
concern about the relevance of these studies performed in animals for predicting human toxicity (Basketter et al., 2012; Chen
et al., 2014; Hengstler et al., 1999; Olson et al., 2000). Different organizations (FDA, EPA, EMEA) and initiatives (REACH,
TSCA and the EU Cosmetic Directive) are pushing in vitro
methods in the chemical toxicity evaluation process.
RDT includes chronic adverse effects on major organs. On
the one hand, the assessment of RDT requires lengthy in vivo
experiments, which are difficult to model in vitro. On the other
hand, inter-species differences can limit the usefulness of animal data for the prediction of human hazard in this area (Leist
and Hartung, 2013). In vitro methods based on human cell
lines may provide more human-relevant information (Pfaller
et al., 2001). Biological models for different organs, e.g., liver,
kidney, lung or brain, have been established, and new culture
techniques, especially in form of 3D organoids, are expected to
solve present issues about long-term culturing, absence of relevant inflammatory and immune cells (Hengstler et al., 2012)
and availability of fully mature cell phenotypes. Stem cells,
especially pluripotent stem cells, will be a major source of tissues and cells not available otherwise. Therefore, research on
the generation of 2D cultures and 3D tissues from stem cells
is of high importance. One of the approaches in this direction
is the European SEURAT-1 project (following the long-term
strategic target: “Safety Evaluation Ultimately Replacing Animal Testing”, http://www.seurat-1.eu). It started in 2011 with
50 million € joint funding from the European Commission and
Cosmetics Europe and is focusing on the development of nonanimal test systems in the field of repeat dose systemic toxicity
following a case study approach based on the AOP concept.
The Tox21 consortium and the US EPA's ToxCastTM activity in
the USA (Dix et al., 2007; Judson et al., 2010, 2014) as well as
other activities in Europe and worldwide take similar or complementary approaches (NRC, 2007; Adler et al., 2011; Basketter et al., 2012; Judson et al., 2012; Leist et al., 2012b). Key to
all these activities is the concept that most late (longer term)

6 http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2012)10/part1&doclanguage=en
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effects of chemicals will be predicted from the early changes
they cause in cellular signaling and regulation (Kleensang et
al., 2014; Blaauboer et al., 2012). Therefore, signaling pathway identification and analysis is a crucial research necessity
in toxicology, and very detailed quantitative information needs
to be derived (Fig. 12) to use such data for systems biology
modeling (Jennings et al., 2013; Krug et al., 2014; Hartung et
al., 2012). Toxicogenomics technologies (Ramirez et al., 2013)
are important tools that cover a multitude of cellular events.
However, it is important to apply them to the right biological
models. For instance, monocultures can hardly model the inflammatory responses frequently seen after long-term exposure
to hazardous chemicals.
For repeated dose toxicity, two different approaches are taken in the development of alternative methods: (a) substitution
of animals by a battery of relatively complex surrogate models that reflect important features of target tissues and organs.
They often use ‘apical’ phenotypic endpoints (e.g., cell death
markers) as readouts; (b) an integrated and tiered systems biology approach based on mechanistic endpoints and using the
vast knowledge on biological regulation and homeostasis. Pathways-of-toxicity (PoT), emerging from such approaches, will
guide hazard evaluation and risk assessment when combined
with toxicokinetics modelling (Hartung and McBride, 2011;
Boekelheide and Andersen, 2010). The two types of approaches
may also be combined.

Fig. 12: Illustration of the different deviations of signals
(physiological cellular responses) that need to be measured
by modern in vitro methods
The normal cellular response is shown in blue. This is meant to
symbolize any cellular function, such as a muscle contraction, an
electrical signal in neurons or the regulation of glucose. Red and
white curves exemplify different toxic responses. The examples
show that key parameters need to be measured at high temporal
and spatial resolution and over many concentrations to be sure the
whole range of toxicological reactions is covered. “Toxicity” is in
many cases not a simple decrease or absence of a response, but
too much or wrong timing can be equally problematic.
Altex 31, 3/14

In summary, repeated dose toxicity will probably be the last
method to be replaced, the use of PoT and new culture systems
combined with new technologies and sharing of data on pharmaceutical case studies could be the opportunity to reduce the
need for such expensive and long-term studies.
6.3 Toxicokinetics and quantitative
in vitro – in vivo extrapolation (qIVIVE)

To relate data from non-animal test systems to the human situation, the in vitro concentration levels need to be correlated with
the real exposure in vivo. Procedures for such extrapolations
(qIVIVE) have been established (Fig. 13). The starting point is
a determination of the “real” toxicant concentration that a cell
is exposed to. This may be different from the nominal concentration, because of evaporation, metabolism, binding to plastic
or uneven distribution in cells. Next, a physiologically-based
pharmacokinetic (PBPK) model would be constructed for absorption and distribution in the whole organism, followed by
metabolism and excretion. In vitro test systems to predict drug

Fig. 13: Schematic explanation of quantitative
in vitro – in vivo extrapolation (qIVIVE)
The qIVIVE procedure is considered a pivotal step in the use of in
vitro data for the risk assessment process. In vitro toxicity assays
provide a benchmark concentration (BMC), i.e., a concentration
above which a chemical is considered to be toxic in this system.
The BMC is used as the point of departure (POD) for further
qIVIVE steps. It allows the calculation of the corresponding
human plasma concentration (PC). By taking into account in vitro
data on metabolic conversion, human physiology and metabolic
parameters, the human equivalent dose can be estimated. This is
the starting point of the risk assessment process.
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Fig. 14: Roadmap to animal-free toxicokinetic predictions
The experts in the area of toxicokinetics identified research areas
requiring further work to obtain human-relevant toxicokinetic data
on xenobiotics independent of animal experiments.

metabolism or certain distribution parameters can provide data
for such modeling (Vinci et al., 2012; Gebhardt et al., 2003) but
better assays are still required for local specialized metabolism,
distribution mediated by transporters, and for excretion processes (e.g., in the kidney). Altogether, this area is far advanced,
e.g., for drug development, but its general application for chemicals requires further development (Bessems et al., 2014). Detailed case studies are required to explore the performance of
currently available methods (Fig. 14).

ductive toxicity testing has shown high background variability
(even among untreated control animals) and is characterized by
low species concordance (ToxCast™, for example, showed 60%
concordance between rat and rabbit studies; and 56% concordance between zebrafish and rat). In some cases, to overcome
low sensitivity, studies in a second species may be requested
by regulators. However, the two-species approach increases
both the cost of the studies and the false-positive rates dramatically (Hartung, 2009). For this reason, in 2009, a revision of the
REACH legislation reduced the use of a second species.
Further progress in this area would be accelerated by regulatory steps that preclude the use of in vivo data unless they
come from a formally validated model and therefore have a
known predictivity (Carney et al., 2011). Uses of the zebrafish
assay (Selderslaghs et al., 2011; Padilla et al., 2012; Truong et
al., 2014), the embryonic stem cell test (EST) (van Dartel and
Piersma, 2011; Seiler and Spielmann, 2011) and further developments on the basis of ReProTect test systems (Piersma, 2010)
could immediately fill the gap until assays based on human
cells become available. The field is developing very dynamically, and, especially in the area of developmental neurotoxicity, many new test systems are emerging (Zimmer et al., 2014;
Smirnova et al., 2014; Leist et al., 2013; Bal-Price et al., 2012).
The new assays will need to be assembled into an advanced test
battery using concepts of ITS design (Fig. 15).
The ReProTect project assembled 35 European partners
from academia, SMEs (Small-Medium Enterprises) and governmental institutes in order to develop in vitro reproductive
toxicity approaches (http://www.reprotect.eu/). The scientific
problem of identifying non-animal test methods in this field
was addressed (Hareng et al., 2005). The project was based on
a battery of in vitro methods that covered different steps of the
reproductive cycle (Fig. 16). In a so-called “feasibility study”
conducted at the end of the project, 10 blinded chemicals were
tested by the consortium. Effects on 3 endpoints, namely male
fertility, female fertility and embryotoxicity were predicted. The
results of the feasibility study demonstrated that the vast majority of the predictions made were correct (Schenk et al., 2010).

6.4 Reproductive toxicity

Reproductive toxicology, including developmental toxicology, is a particularly difficult field as far as animal-to-human
predictions are concerned (Knudsen et al., 2011; Makris et al.,
2011). Reproductive toxicity aims to assess possible hazard to
the reproductive cycle, with a high interest in the early stages
of embryonic development (embryotoxicity). Tests like the
two-generation study are among the most costly and require
up to 3,200 animals per substance (Hartung, 2008; Rovida and
Hartung, 2009). This makes it impossible to test the enormous
amount of chemicals present in the market, leading to a lack of
information on reproduction and development toxicity of tens
of thousands chemicals. Moreover, animal-based tests offer little mechanistic insight into a chemical’s toxic mode-of-action
(MoA) (Knudsen et al., 2013; Knudsen, 2013). Animal repro350

Fig. 15: The roadmap for animal-free reproductive toxicity
predictions
In the area of reproductive toxicity the experts suggested, in
addition to the points summarized in Figures 4 and 6, to include
several specific measures and research lines to be followed.
Altex 31, 3/14

Leist et al.

Fig. 16: Examples of a test battery
addressing a highly complex
toxicological endpoint
The reproductive cycle with its
four main phases is the target of
reproductive toxicants. The FP6 EU
project ReProTect established an
in vitro test battery for reproductive
toxicity testing covering the
reproductive cycle with a series of
individual tests. Each test system
covers a small part of the reproductive
cycle. The names of the different tests
are depicted outside and inside the
circle, indicating which part of the
developmental process is modeled.
For full explanation see http://axlr8.eu/
axlr8-2010-progress-report.pdf

In the follow-up European project ChemScreen (http://www.
chemscreen.eu) 12 chemicals were tested for embryotoxicity in
a final performance test. The battery correctly detected 11 out
of 12 compounds tested. The consortium concluded that “this
study illustrates added value of combining assays that contain
complementary biological processes and mechanisms, increasing predictive value of the battery over individual assays”
(Piersma et al., 2013).
In silico models (e.g., the US EPA̓s Virtual Embryo project)
have also shown potential application in the reproductive toxicology field. It is expected that ultimately a computer model
that simulates cellular function in the growing embryo can be
used to determine the effects of teratogens. Some promising first
results come from an in silico modeling platform: A novel multi-cellular agent-based model (ABMs) of vasculogenesis using
the CompuCell3D (http://www.compucell3d.org/) modeling environment supplemented with semi-automatic knowledgebase
creation has been developed by EPA. Dynamic cell ABMs have
been shown to simulate complex developing systems and, consequently, display a potential to simulate adverse effects (Kleinstreuer et al., 2013; Hester et al., 2011; Shirinifard et al., 2013)
and aberrant tissue fusion (Ray and Niswander, 2012).

not positive (Basketter et al., 2012). The correlation of findings
in rats and mice is less than 60%, even less if the site of cancer
in the organism is considered. The experts suggested a thorough
evaluation of the test, taking into account the principles of evidence-based toxicology (Hoffmann and Hartung, 2006b). This
might lead to an abolition of the in vivo assay (Fig. 17). Chemical carcinogenicity may be based either on genotoxic or nongenotoxic (epigenetic) mechanisms (Oliveira et al., 2007). Alternative methods for the determination of genotoxicity have been
in use for over 40 years. An ITS has been suggested to combine
such available methods (Pfuhler et al., 2010; Aldenberg and Jaworska, 2010). Testing for non-genotoxic carcinogens has proven more difficult, but good results have been obtained recently
by various cell transformation assays (Vanparys et al., 2011). A
combination of mutagenesis assays, tests for DNA damage, cell
transformation assays and targeted tests for frequent epigenetic

6.5 Carcinogenicity

At present, the carcinogenicity hazard of chemicals is determined by a costly and lengthy animal test, the “cancer bioassay”,
although its relevance for human health is seriously doubted (Alden et al., 1996; Knight, 2007; Gottmann et al., 2001). Results of
more than 3.500 cancer bioassays, which cost about € 800,000
per substance and species, are publically available: 53% of all
substances tested were positive, suggesting an enormous falsepositive rate, but still some accepted human carcinogens were
Altex 31, 3/14

Fig. 17: Roadmap for animal-free carcinogenicity predictions
In the area of carcinogenicity the experts suggested, in addition
to the points summarized in Figures 4 and 6, to include several
specific measures and research lines to be followed.
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mechanisms (e.g., nuclear receptor activation) will most likely
form the basis for a future ITS. Most elements are available in
some form, but they will require further development and optimization for satisfactory predictivity (Fig. 17).
7 Evaluation of test system performance

Evaluation of test system performance has classically considered three aspects (Fig. 18): (1) the technical reliability of the
test; (2) the scientific background, rationale and scope; (3) the
correlation of test data with a gold standard (e.g., animal data).
The latter point has also been called predictivity (Hartung et al.,
2004; Hoffmann and Hartung, 2006a; Moore et al., 2009). The
validation procedure has until now followed very strict and rigid
rules in the field of chemical testing. This has led to high costs
and long delays before new assays were introduced. Moreover,
the definition of assay predictivity on the basis of animal data
has proven to be problematic because of the shortcomings of the
in vivo experiments. Therefore, new validation concepts have
to be considered. For instance, high throughput screening assays need to be treated differently from other tests as, e.g., ring
trials cannot be performed when certain robotics equipment is
available only in one place (Judson et al., 2013). In cases where
predictivity cannot be determined from correlation studies, en-

Fig. 18: New validation approach for novel toxicity tests
At present, test validation relies on three pillars: reliability,
scientific basis and predictivity. Predictivity has in practical
terms been determined by the correlation of in vitro test results
with animal data. This approach is not possible for many of the
toxicity domains discussed here and many of the assays that
are developed are part of a test battery. Future validation must
therefore rely on two pillars: Even more focus is required on test
quality (reliability). Moreover, the scientific basis of a test needs to
be broadened to provide a rationale for the predictive capacity of
the test, not based on statistical correlation but based on scientific
(mechanistic) explanations.

Fig. 19: Vision for the future of toxicity testing
The current approach is first to test unknown chemicals in animal tests. This limits overall throughput and leads to a high rate of false
positives and false negatives. Mixtures are hardly ever tested because of the limitation of resources. High costs in combination with a
low predictivity lead to many cases of “no testing”. Mechanistic studies are only carried out in few cases of particular interest to identify
the factors causing the toxicity. The new approach, suggested here, is based on 21st century in silico and in vitro methods identifying
PoT. This will in most cases lead to an amount of data that is sufficient to decide whether a substance is toxic (positive) or non-toxic
(negative) for the intended scenario. Only in few cases, when not enough information can be obtained, will animal tests be performed as
an additional source of information. Good information can be provided on all chemicals and, due to the high throughput of the approach,
also on mixtures.
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tirely different approaches need to be considered. Mechanistic
validation, i.e., focus on the scientific background and consistency of an assay (Hartung et al., 2013a; Leist et al., 2012a), is
the most promising general option. For specialized assays, e.g.,
within a test battery or as the basis of a screening approach,
the test performance will also need to be judged according to
its fit for the specific purpose (Fig. 18). The concept of flexible
evaluations of test system performance has been pioneered in
the field of drug discovery. Fit-for-purpose evaluation and rating of test predictivity based on the scientific rationale of a test
are commonplace in this field, and this experience could help to
establish faster and more efficient assay evaluation procedures
for chemicals, cosmetics and pesticides. In the discussion on
test system predictivity it is important to keep in mind that test
reliability will always be a necessary, absolutely mandatory
condition, whatever evaluation process is chosen. The progress
and acceptance of non-animal based testing will depend on this
criterion and its strict implementation in the field (Leist et al.,
2010).
8 The future of toxicity testing

The participants of the roadmap consensus symposium envisaged that two key features will distinguish the future from the
present toxicity testing (Fig. 19). First, the present animal-based
testing (sometimes followed by in vitro tests to supply mechanistic information) will be substituted by ITS using in vitro
and in silico approaches (sometimes followed by animal tests,
where further data are needed). Second, according to the vision
for a new toxicology, data will be generated for every chemical
and possibly also for important mixtures. This contrasts with
the present situation, in which hardly any data is available on
many chemicals (Crofton et al., 2012) and many tests are being waived. Moreover, a large part of the available data lacks
mechanistic background and consistency controls. It therefore
cannot be used to supply information concerning adverse outcome pathways. Despite the many shortcomings and, in particular, a lack of formal validation, animal data are still being used
as gold standard. This contributes to an underestimation of the
success of non-animal methods. The expectations regarding scientific validity and predictivity are usually higher for alternative
methods than for the respective in vivo models. This is a key issue for the roadmap initiative, as the primary goal is to provide
methods that are as good as animal models (not better). This
goal might already have been reached in some areas. The future
goals would then be to further improve the quality of safety testing beyond that of animal experiments.
As detailed already in the NRC report on the vision for toxicity testing in the 21st century (NRC, 2007; Leist et al., 2008a),
the radically new approach to risk assessment has large economic and scientific advantages over the present animal-based
system. The roadmap outlined in this overview highlights important steps towards this goal. All experts agreed that considerable work is still needed, but there was also strong consensus
that already an impressive advance has been achieved and that
the goal is well worth the required efforts.
Altex 31, 3/14
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